Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey

by Steegmann, J. L., Sánchez Torres, J. M., Colomer, R., Vaz, Á., López, J., Jalón, I., Provencio, M., González-Martín, A., Pérez, M.
Published 2012

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

by le Coutre, P D, Hughes, T P, Mahon, F-X, Kim, D-W, Steegmann, J L, Shah, N P, Gooden, K, Wallis, N, Cortes, J E
Published 2016

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

by Steegmann, J L, Baccarani, M, Breccia, M, Casado, L F, García-Gutiérrez, V, Hochhaus, A, Kim, D-W, Kim, T D, Khoury, H J, Le Coutre, P, Mayer, J, Milojkovic, D, Porkka, K, Rea, D, Rosti, G, Saussele, S, Hehlmann, R, Clark, R E
Published 2016

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

by Hochhaus, A, Rosti, G, Cross, N C P, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, Giles, F J
Published 2016